Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing
Executive Summary
Ranbaxy needs a relatively quick win in its lawsuit against FDA if it hopes to benefit from the 180-day exclusivity it is claiming for Zocor 80 mg
You may also be interested in...
FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy
FDA is assessing its next step following an appeals court ruling confirming that the agency's position on delisting patents is inconsistent with Hatch/Waxman
FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy
FDA is assessing its next step following an appeals court ruling confirming that the agency's position on delisting patents is inconsistent with Hatch/Waxman
Ivax to join Zocor court battle
Ivax files suit against FDA on Nov. 7 claiming exclusivity rights for Merck's cholesterol-lowering agent Zocor (simvastatin) following an Oct. 24 letter from the agency denying its citizen petition. Ivax claims exclusivity rights for Zocor 5 mg, 10 mg, 20 mg and 40 mg strengths and seeks to have two Merck patents re-listed in the "Orange Book." Ranbaxy filed suit against FDA Sept. 16 claiming exclusivity rights for the 80 mg dose of Zocor (1"The Pink Sheet" Oct. 31, 2005, p. 19). Both Ivax and Ranbaxy need a quick win to settle the matter; the compound patent for Zocor is set to expire June 23, 2006...